Drug,Chemical Structure,Adverse Effect / Toxicity,Species,Dose,Dose Type,Route,Source,Source Link,Year,no_stereoisomer
Acitretin,COC1=CC(C)=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(C)=C1C,Hepatocellular injury,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 019821 Part 01, page:1 PDF 7773k",https://www.pharmapendium.com/browse/fda/Acitretin/1a0cb7a639fe6c5d73334f9d95bc1bc6?reference=1,1996.0,COC1=CC(C)=C(\C=C\C(C)=C\C=C\C(C)=C\C(O)=O)C(C)=C1C
Alectinib Hydrochloride,CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C2=O)C2=C(N1)C=C(C=C2)C#N,Hepatocellular injury,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 208434/S-000 Part 04, page:32 PDF 1103k",https://www.pharmapendium.com/browse/fda/Alectinib Hydrochloride/08016b74dd48063d91356464db4510cb?reference=32,2015.0,CCC1=CC2=C(C=C1N1CCC(CC1)N1CCOCC1)C(C)(C)C1=C(C2=O)C2=C(N1)C=C(C=C2)C#N
Amiodarone Hydrochloride,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,Hepatocellular injury,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Approval Package 018972/S-014 Part 12, page:42 PDF 5420k",https://www.pharmapendium.com/browse/fda/Amiodarone Hydrochloride/4458ab986d830273f3d667d2639687ad?reference=42,1983.0,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1
Amphotericin B Liposome,C[C@@H]1OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@]2(O)C[C@H](O)[C@H]([C@H](C[C@@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[C@H](C)[C@@H](O)[C@H]1C)O2)C(O)=O,Hepatocellular injury,Human,-0.0,Repeated,Intravenous,"FDA approval package document: Medical Officer Review 050740/S-000 Part 02, page:7 PDF 1675k",https://www.pharmapendium.com/browse/fda/Amphotericin B Liposome/78e250c7992db1f3a1a76c3e77bdf637?reference=7,1997.0,C[CH]1OC(=O)C[CH](O)C[CH](O)CC[CH](O)[CH](O)C[CH](O)C[C]2(O)C[CH](O)[CH]([CH](C[CH](O[CH]3O[CH](C)[CH](O)[CH](N)[CH]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\[CH](C)[CH](O)[CH]1C)O2)C(O)=O
Anidulafungin,CCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[C@H]1C[C@@H](O)[C@@H](O)NC(=O)[C@@H]2[C@@H](O)[C@@H](C)CN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC1=O)[C@@H](C)O)[C@H](O)[C@@H](O)C1=CC=C(O)C=C1)[C@@H](C)O,Hepatocellular injury,Human,-2.3010299956639813,Repeated,Intravenous,"FDA approval package document: Patient Information Sheet 021632/S-000; 021948/S-000, page:1 PDF 219k",https://www.pharmapendium.com/browse/fda/Anidulafungin/c844d8d0baf33cf36ccc3556ffed12a4?reference=1,2006.0,CCCCCOC1=CC=C(C=C1)C1=CC=C(C=C1)C1=CC=C(C=C1)C(=O)N[CH]1C[CH](O)[CH](O)NC(=O)[CH]2[CH](O)[CH](C)CN2C(=O)[CH](NC(=O)[CH](NC(=O)[CH]2C[CH](O)CN2C(=O)[CH](NC1=O)[CH](C)O)[CH](O)[CH](O)C1=CC=C(O)C=C1)[CH](C)O
Balsalazide Disodium,OC1=CC=C(C=C1C([O-])=O)\N=N\C1=CC=C(C=C1)C(=O)NCCC([O-])=O,Hepatocellular injury,Human,-4.8750612633917,Repeated,Oral,"FDA approval package document: Label 020610/S-014, page:8 PDF 337k",https://www.pharmapendium.com/browse/fda/Balsalazide Disodium/84390a507bff32ec4c79256e84a73323?reference=8,2006.0,OC1=CC=C(C=C1C([O-])=O)\N=N\C1=CC=C(C=C1)C(=O)NCCC([O-])=O
Benoxaprofen,CC(C(O)=O)C1=CC=C2OC(=NC2=C1)C1=CC=C(Cl)C=C1,Hepatocellular injury,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Approval Package 018250 Part 04, page:19 PDF 10386k",https://www.pharmapendium.com/browse/fda/Benoxaprofen/b9ab0cdd250f97cd27dccfe2b18c1c91?reference=19,1976.0,CC(C(O)=O)C1=CC=C2OC(=NC2=C1)C1=CC=C(Cl)C=C1
Bepridil Hydrochloride,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1,Hepatocellular injury,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 019002 Part 03, page:21 PDF 5181k",https://www.pharmapendium.com/browse/fda/Bepridil Hydrochloride/29c2ba52698e32b31cdc937cc5b63b78?reference=21,1990.0,CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1
Bosutinib Monohydrate,COC1=C(Cl)C=C(Cl)C(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C1,Hepatocellular injury,Human,-2.7781512503836434,Repeated,Oral,"EMA approval document: ANNEX I, page:44 PDF 539k",https://www.pharmapendium.com/browse/ema/Bosutinib Monohydrate/137a7ce8622db12be304e68713ed1bbe?reference=44,2021.0,COC1=C(Cl)C=C(Cl)C(NC2=C(C=NC3=CC(OCCCN4CCN(C)CC4)=C(OC)C=C23)C#N)=C1
Brigatinib,COC1=CC(=CC=C1NC1=NC(NC2=CC=CC=C2P(C)(C)=O)=C(Cl)C=N1)N1CCC(CC1)N1CCN(C)CC1,Hepatocellular injury,Human,-2.255272505103306,Repeated,Oral,"EMA approval document: Assessment Report EMA/140650/2020; EMEA/H/C/004248/II/0003, page:79 PDF 5666k",https://www.pharmapendium.com/browse/ema/Brigatinib/90bc8094fb1cd300b7ee28bf690bb302?reference=79,2020.0,COC1=CC(=CC=C1NC1=NC(NC2=CC=CC=C2P(C)(C)=O)=C(Cl)C=N1)N1CCC(CC1)N1CCN(C)CC1
Bupropion Hydrochloride,CC(NC(C)(C)C)C(=O)C1=CC=CC(Cl)=C1,Hepatocellular injury,Human,-2.6532125137753435,Repeated,Oral,"FDA approval package document: Approval Package 077284 Part 01, page:17 PDF 6399k",https://www.pharmapendium.com/browse/fda/Bupropion Hydrochloride/9bbc6b7c1882de700b7495ee09188aae?reference=17,2006.0,CC(NC(C)(C)C)C(=O)C1=CC=CC(Cl)=C1
Cabotegravir Sodium,[H][C@@]12CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C([O-])=C3C(=O)N1[C@@H](C)CO2,Hepatocellular injury,Human,-2.6020599913279625,Repeated,Intramuscular,"EMA approval document: Public Assessment Report EMA/586324/2020; EMEA/H/C/004976/0000, page:119 PDF 8611k",https://www.pharmapendium.com/browse/ema/Cabotegravir Sodium/7d31e8568fdb1789517380a5b98893eb?reference=119,2020.0,[H][C]12CN3C=C(C(=O)NCC4=C(F)C=C(F)C=C4)C(=O)C([O-])=C3C(=O)N1[CH](C)CO2
Cannabidiol,CCCCCC1=CC(O)=C([C@@H]2C=C(C)CC[C@H]2C(C)=C)C(O)=C1,Hepatocellular injury,Human,-1.3010299956639813,Repeated,Oral,"EMA approval document: Assessment Report EMA/428872/2019, page:7 PDF 375k",https://www.pharmapendium.com/browse/ema/Cannabidiol/4fa74c295ee98d9d3ca342fd727b3cff?reference=7,2019.0,CCCCCC1=CC(O)=C([CH]2C=C(C)CC[CH]2C(C)=C)C(O)=C1
Captopril,C[C@H](CS)C(=O)N1CCC[C@H]1C(O)=O,Hepatocellular injury,Human,-0.47712125471966244,Repeated,Oral,"FDA approval package document: Approval Package 018343/S-013, S-005, S-018 Part 02, page:22 PDF 3959k",https://www.pharmapendium.com/browse/fda/Captopril/34babee9aef97c53c91b863fc75e8345?reference=22,1980.0,C[CH](CS)C(=O)N1CCC[CH]1C(O)=O
Carbamazepine,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12,Hepatocellular injury,Human,-3.0791812460476247,Repeated,Oral,"FDA approval package document: Approval Package 018281/S-003, S-001, S-004, S-005, S-022, S-015, S-006, S-008, S-009; 016608/S-053, S-055, S-056, S-048, S-058, S-059 Part 01, page:11 PDF 4905k",https://www.pharmapendium.com/browse/fda/Carbamazepine/778de86a20d1b2073b14cd08f44f0fe2?reference=11,1981.0,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C12
Cefepime Hydrochloride,CO\N=C(C(=O)N[C@H]1[C@H]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)\C1=CSC(N)=N1,Hepatocellular injury,Human,-3.3010299956639813,Repeated,Parenteral,"FDA approval package document: Approval Package 050679 Part 09, page:14 PDF 8744k",https://www.pharmapendium.com/browse/fda/Cefepime Hydrochloride/eadbdd917f044afcacab4831033bd9d2?reference=14,1996.0,CO\N=C(C(=O)N[CH]1[CH]2SCC(C[N+]3(C)CCCC3)=C(N2C1=O)C(O)=O)\C1=CSC(N)=N1
Ceritinib,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1,Hepatocellular injury,Human,-2.8750612633917,Repeated,Oral,"EMA approval document: Assessment Report EMA/170114/2015; EMEA/H/C/003819/0000, page:97 PDF 3461k",https://www.pharmapendium.com/browse/ema/Ceritinib/625fcc14a77690a19eb6362758b85c7e?reference=97,2015.0,CC(C)OC1=C(NC2=NC=C(Cl)C(NC3=C(C=CC=C3)S(=O)(=O)C(C)C)=N2)C=C(C)C(=C1)C1CCNCC1
Chloral Hydrate,OC(O)C(Cl)(Cl)Cl,Hepatocellular injury,Human,0,Repeated,Oral,Mosby's Drug Consult TM: Chloral Hydrate,https://www.pharmapendium.com/browse/mosby/Chloral Hydrate/Chloral Hydrate#s000715-od,2006.0,OC(O)C(Cl)(Cl)Cl
Cinchophen,OC(=O)C1=C2C=CC=CC2=NC(=C1)C1=CC=CC=C1,Hepatocellular injury,Human,-3.0,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Cinchophen063   ---   JOURNAL:American Journal of Pathology   PAGES:237   VOLUME:7,,1931.0,OC(=O)C1=C2C=CC=CC2=NC(=C1)C1=CC=CC=C1
Citalopram Hydrobromide,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1,Hepatocellular injury,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020822/S-000 Part 04, page:2 PDF 1014k",https://www.pharmapendium.com/browse/fda/Citalopram Hydrobromide/add4a00a2cd8ac4af89f5e7f89bd2d8e?reference=2,1998.0,CN(C)CCCC1(OCC2=C1C=CC(=C2)C#N)C1=CC=C(F)C=C1
Darunavir Ethanolate,[H][C@]12OCC[C@@]1([H])[C@H](CO2)OC(=O)N[C@@H](CC1=CC=CC=C1)[C@H](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1,Hepatocellular injury,Human,-3.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021976/S-000 Part 02, page:28 PDF 5706k",https://www.pharmapendium.com/browse/fda/Darunavir Ethanolate/4e04c53da33bc28af175a4f8ed94ab9d?reference=28,2006.0,[H][C]12OCC[C]1([H])[CH](CO2)OC(=O)N[CH](CC1=CC=CC=C1)[CH](O)CN(CC(C)C)S(=O)(=O)C1=CC=C(N)C=C1
Deferasirox,OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O,Hepatocellular injury,Human,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021882/S-000 Part 01, page:6 PDF 7036k",https://www.pharmapendium.com/browse/fda/Deferasirox/7eefb7d3bd476193f25da92aba7eadf3?reference=6,2005.0,OC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1O
Desloratadine,ClC1=CC2=C(C=C1)\C(=C1\CCNCC1)C1=C(CC2)C=CC=N1,Hepatocellular injury,Human,-0.6989700043360189,Repeated,Oral,"EMA approval document: Procedural Steps EMA/85131/202, page:17 PDF 309k",https://www.pharmapendium.com/browse/ema/Desloratadine/d20b6065bc6c1dbf415ecc55c8ed630a?reference=17,2021.0,ClC1=CC2=C(C=C1)\C(=C1\CCNCC1)C1=C(CC2)C=CC=N1
Diclofenac Sodium,[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl,Hepatocellular injury,Human,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Approval Package 019201/S-001, S-002, S-003, S-005, S-007, S-009, S-010, S-013, S-014, S-015, S-019, S-021 Part 04, page:20 PDF 4845k",https://www.pharmapendium.com/browse/fda/Diclofenac Sodium/50a02054fb1c7b2f7fc0318a7d09e44c?reference=20,1988.0,[O-]C(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl
Diltiazem Hydrochloride,COC1=CC=C(C=C1)[C@@H]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[C@@H]1OC(C)=O,Hepatocellular injury,Human,-2.5563025007672873,Repeated,Oral,"FDA approval package document: Approval Package 019471/S-004 Part 01, page:14 PDF 3362k",https://www.pharmapendium.com/browse/fda/Diltiazem Hydrochloride/5d82eb501029b1d8a4978118c0a07475?reference=14,1988.0,COC1=CC=C(C=C1)[CH]1SC2=CC=CC=C2N(CCN(C)C)C(=O)[CH]1OC(C)=O
Dofetilide,CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1,Hepatocellular injury,Human,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020931 Part 02, page:8 PDF 1717k",https://www.pharmapendium.com/browse/fda/Dofetilide/c9f3f3e4a54602918eaaf461146417f9?reference=8,1998.0,CN(CCOC1=CC=C(NS(C)(=O)=O)C=C1)CCC1=CC=C(NS(C)(=O)=O)C=C1
Dolutegravir Sodium,[H][C@]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N1[C@H](C)CCO2,Hepatocellular injury,Human,-2.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 204790 Part 04, page:28 PDF 7848k",https://www.pharmapendium.com/browse/fda/Dolutegravir Sodium/1ad0a2b9727ce58261902f144c3cb335?reference=28,2012.0,[H][C]12CN3C=C(C(=O)NCC4=CC=C(F)C=C4F)C(=O)C([O-])=C3C(=O)N1[CH](C)CCO2
Doravirine,CN1C(=O)NN=C1CN1C=CC(=C(OC2=CC(=CC(Cl)=C2)C#N)C1=O)C(F)(F)F,Hepatocellular injury,Human,-0.3010299956639812,Repeated,Oral,"EMA approval document: ANNEX I, page:14 PDF 282k",https://www.pharmapendium.com/browse/ema/Doravirine/e83e7b9edeca351f3caebf9e56bc50e4?reference=14,2019.0,CN1C(=O)NN=C1CN1C=CC(=C(OC2=CC(=CC(Cl)=C2)C#N)C1=O)C(F)(F)F
Doripenem,[H][C@]12[C@@H](C)C(S[C@@H]3CN[C@H](CNS(N)(=O)=O)C3)=C(N1C(=O)[C@]2([H])[C@@H](C)O)C(O)=O,Hepatocellular injury,Human,-0.9030899869919435,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 022106/S-000 Part 04, page:31 PDF 5980k",https://www.pharmapendium.com/browse/fda/Doripenem/b2edffb45524b9d90bae2b8780e60cf2?reference=31,2007.0,[H][C]12[CH](C)C(S[CH]3CN[CH](CNS(N)(=O)=O)C3)=C(N1C(=O)[C]2([H])[CH](C)O)C(O)=O
Dronedarone Hydrochloride,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12,Hepatocellular injury,Human,-2.9030899869919438,Repeated,Intramuscular,"EMA approval document: Assessment Report EMEA/H/C/1043/A20/005, page:20 PDF 943k",https://www.pharmapendium.com/browse/ema/Dronedarone Hydrochloride/ac8f06b056b2958a2f0f1a402458ce78?reference=20,2011.0,CCCCN(CCCC)CCCOC1=CC=C(C=C1)C(=O)C1=C(CCCC)OC2=CC=C(NS(C)(=O)=O)C=C12
Duloxetine Hydrochloride,CNCC[C@H](OC1=C2C=CC=CC2=CC=C1)C1=CC=CS1,Hepatocellular injury,Human,-2.0791812460476247,Repeated,Oral,"EMA approval document: ANNEX I, page:6 PDF 322k",https://www.pharmapendium.com/browse/ema/Duloxetine Hydrochloride/a7dc7a1c765c4e8cf07aa7f5683d81b6?reference=6,2020.0,CNCC[CH](OC1=C2C=CC=CC2=CC=C1)C1=CC=CS1
Duvelisib,C[C@H](NC1=NC=NC2=C1N=CN2)C1=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1,Hepatocellular injury,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Label 211155/S-001, page:11 PDF 513k",https://www.pharmapendium.com/browse/fda/Duvelisib/a9516e6c84a6d9d5e3d23f51a2bb83e8?reference=11,2018.0,C[CH](NC1=NC=NC2=C1N=CN2)C1=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1
Epoprostenol Sodium,CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)C[C@@H]2O\C(C[C@H]12)=C/CCCC([O-])=O,Hepatocellular injury,Human,-7.681241237375588,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 020444/S-003 Part 01, page:19 PDF 1223k",https://www.pharmapendium.com/browse/fda/Epoprostenol Sodium/e45112e315c6961c805c3f17ed128c8c?reference=19,1999.0,CCCCC[CH](O)\C=C\[CH]1[CH](O)C[CH]2O\C(C[CH]12)=C/CCCC([O-])=O
Estradiol,[H][C@]12CC[C@]3(C)[C@@H](O)CC[C@@]3([H])[C@]1([H])CCC1=C2C=CC(O)=C1,Hepatocellular injury,Human,-1.146128035678238,Repeated,Skin,"FDA approval package document: Label 020375/S-023, page:25 PDF 464k",https://www.pharmapendium.com/browse/fda/Estradiol/00a8e0ab0e20243d8f3c0567acb225de?reference=25,2006.0,[H][C]12CC[C]3(C)[CH](O)CC[C]3([H])[C]1([H])CCC1=C2C=CC(O)=C1
Eszopiclone,CN1CCN(CC1)C(=O)O[C@@H]1N(C(=O)C2=C1N=CC=N2)C1=NC=C(Cl)C=C1,Hepatocellular injury,Human,-0.3010299956639812,Repeated,Oral,Reference from PharmaPendium Published Toxicity: eszopiclone_cia-2-313   ---   JOURNAL:Clinical Interventions in Aging   PAGES:313   VOLUME:2,,2007.0,CN1CCN(CC1)C(=O)O[CH]1N(C(=O)C2=C1N=CC=N2)C1=NC=C(Cl)C=C1
Etodolac,CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(O)=O,Hepatocellular injury,Human,-1.2041199826559248,Repeated,Oral,"FDA approval package document: Approval Package 018922/S-007, S-008, S-013, S-014, S-015 Part 07, page:8 PDF 4550k",https://www.pharmapendium.com/browse/fda/Etodolac/b2d3917f5dc5458cceb33c6f69f0163b?reference=8,1991.0,CCC1=CC=CC2=C1NC1=C2CCOC1(CC)CC(O)=O
Famotidine,N\C(N)=N/C1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1,Hepatocellular injury,Human,-0.0,Repeated,Oral,"FDA approval package document: Approval Package 020752/S-005; 019527/S-024; 019462/S-030, page:59 PDF 6534k",https://www.pharmapendium.com/browse/fda/Famotidine/90f64d44c3867c64c3a853f5536ea5a9?reference=59,2002.0,N\C(N)=N/C1=NC(CSCCC(=N)NS(N)(=O)=O)=CS1
Febuxostat,CC(C)COC1=CC=C(C=C1C#N)C1=NC(C)=C(S1)C(O)=O,Hepatocellular injury,Human,-2.0791812460476247,Repeated,Oral,"EMA approval document: ANNEX I, page:69 PDF 554k",https://www.pharmapendium.com/browse/ema/Febuxostat/90530b38818991c7a21225414abfe220?reference=69,2020.0,CC(C)COC1=CC=C(C=C1C#N)C1=NC(C)=C(S1)C(O)=O
Fenofibrate,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1,Hepatocellular injury,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 019304/S-005, page:28 PDF 1146k",https://www.pharmapendium.com/browse/fda/Fenofibrate/635bb0559900bac359b68e1c8d2c4bd0?reference=28,2000.0,CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C1=CC=C(Cl)C=C1
Fexofenadine Hydrochloride,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1,Hepatocellular injury,Human,-2.255272505103306,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 201373/S-000 Part 11, page:5 PDF 876k",https://www.pharmapendium.com/browse/fda/Fexofenadine Hydrochloride/d7059e44b20a49f9940c212d18b49443?reference=5,2010.0,CC(C)(C(O)=O)C1=CC=C(C=C1)C(O)CCCN1CCC(CC1)C(O)(C1=CC=CC=C1)C1=CC=CC=C1
Fingolimod Hydrochloride,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1,Hepatocellular injury,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022527/S-000 Part 15, page:12 PDF 628k",https://www.pharmapendium.com/browse/fda/Fingolimod Hydrochloride/e915594d2e28cdace1210195661a719c?reference=12,2009.0,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1
Fluoxetine Hydrochloride,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1,Hepatocellular injury,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 018936, page:75 PDF 2324k",https://www.pharmapendium.com/browse/fda/Fluoxetine Hydrochloride/1e127e48c2431c4d9847a70614888a10?reference=75,1994.0,CNCCC(OC1=CC=C(C=C1)C(F)(F)F)C1=CC=CC=C1
Ganciclovir,NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1,Hepatocellular injury,Human,-3.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020460, page:13 PDF 822k",https://www.pharmapendium.com/browse/fda/Ganciclovir/0d673418432116c7b055082550aec175?reference=13,1996.0,NC1=NC2=C(N=CN2COC(CO)CO)C(=O)N1
Idelalisib,CC[C@H](NC1=C2N=CNC2=NC=N1)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1,Hepatocellular injury,Human,-2.1760912590556813,Repeated,Oral,"EMA approval document: ANNEX I, page:11 PDF 833k",https://www.pharmapendium.com/browse/ema/Idelalisib/9ecbeed21f64a65ddada4bb787def707?reference=11,2020.0,CC[CH](NC1=C2N=CNC2=NC=N1)C1=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1
Itraconazole,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1,Hepatocellular injury,Human,-2.3010299956639813,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 020657/S-004, S-005; 020966/S-001, S-003, S-004 Part 02, page:44 PDF 1539k",https://www.pharmapendium.com/browse/fda/Itraconazole/8abe09ae3d4a001d94f882ebd0a3cdbb?reference=44,2000.0,CCC(C)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OCC2COC(CN3C=NC=N3)(O2)C2=CC=C(Cl)C=C2Cl)C=C1
Ketoconazole,[H][C@]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C@@](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl,Hepatocellular injury,Human,-3.0791812460476247,Repeated,Oral,"EMA approval document: ANNEX I, page:17 PDF 553k",https://www.pharmapendium.com/browse/ema/Ketoconazole/8d2315e4697688e9c94ee9b957e597c1?reference=17,2020.0,[H][C]1(COC2=CC=C(C=C2)N2CCN(CC2)C(C)=O)CO[C](CN2C=CN=C2)(O1)C1=CC=C(Cl)C=C1Cl
Ketoprofen,CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1,Hepatocellular injury,Human,-2.0,Repeated,Oral,"FDA approval package document: Medical Officer Review 020429 Part 02, page:24 PDF 1711k",https://www.pharmapendium.com/browse/fda/Ketoprofen/294fff90244c022796a65f8836bc24b2?reference=24,1995.0,CC(C(O)=O)C1=CC=CC(=C1)C(=O)C1=CC=CC=C1
Lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,Hepatocellular injury,Human,-1.3979400086720377,Repeated,Oral,"EMA approval document: Assessment Report EMA/232212/2019; EMEA/H/C/000717/II/0102/G, page:59 PDF 2791k",https://www.pharmapendium.com/browse/ema/Lenalidomide/976436ef7b84152fbaa6e7582d1e9873?reference=59,2019.0,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O
Levetiracetam,CC[C@H](N1CCCC1=O)C(N)=O,Hepatocellular injury,Human,-3.4771212547196626,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021035, page:64 PDF 3117k",https://www.pharmapendium.com/browse/fda/Levetiracetam/03d6b5e8161990580f1e2daa4505b7b4?reference=64,1999.0,CC[CH](N1CCCC1=O)C(N)=O
Loratadine,CCOC(=O)N1CC\C(CC1)=C1\C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2,Hepatocellular injury,Human,-1.0,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021952/S-000, page:68 PDF 5746k",https://www.pharmapendium.com/browse/fda/Loratadine/376bf0a7fb839c220039c74cda394827?reference=68,2008.0,CCOC(=O)N1CC\C(CC1)=C1\C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2
Lorlatinib,C[C@H]1OC2=CC(=CN=C2N)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=C1C=C(F)C=C2,Hepatocellular injury,Human,-2.0,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/CHMP/182840/2019; EMEA/H/C/004646/0000, page:120 PDF 7914k",https://www.pharmapendium.com/browse/ema/Lorlatinib/054e6b3d78fb9ec2be0eb4d859c5708f?reference=120,2019.0,C[CH]1OC2=CC(=CN=C2N)C2=C(C#N)N(C)N=C2CN(C)C(=O)C2=C1C=C(F)C=C2
Loxapine Hydrochloride,CN1CCN(CC1)C1=NC2=C(OC3=C1C=C(Cl)C=C3)C=CC=C2,Hepatocellular injury,Human,-2.0,Repeated,Oral,"FDA approval package document: Label 017525/S-051; 017658/S-038; 018039/S-024, page:6 PDF 325k",https://www.pharmapendium.com/browse/fda/Loxapine Hydrochloride/5891388147ae5ecbac6dabcb4b794667?reference=6,2017.0,CN1CCN(CC1)C1=NC2=C(OC3=C1C=C(Cl)C=C3)C=CC=C2
Maraviroc,[H][C@]12CC[C@]([H])(C[C@H](C1)N1C(C)=NN=C1C(C)C)N2CC[C@H](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1,Hepatocellular injury,Human,-3.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022128/S-000, page:24 PDF 8317k",https://www.pharmapendium.com/browse/fda/Maraviroc/e100e3226906927d8e7a780313319af6?reference=24,2007.0,[H][C]12CC[C]([H])(C[CH](C1)N1C(C)=NN=C1C(C)C)N2CC[CH](NC(=O)C1CCC(F)(F)CC1)C1=CC=CC=C1
Mercaptopurine,S=C1NC=NC2=C1NC=N2,Hepatocellular injury,Human,-0.3010299956639812,Repeated,Oral,"EMA approval document: ANNEX I, page:29 PDF 510k",https://www.pharmapendium.com/browse/ema/Mercaptopurine/b044af08a16654e32721c2e21e341e00?reference=29,2021.0,S=C1NC=NC2=C1NC=N2
Methyldopa,C[C@](N)(CC1=CC(O)=C(O)C=C1)C(O)=O,Hepatocellular injury,Human,-3.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 018934, page:17 PDF 4491k",https://www.pharmapendium.com/browse/fda/Methyldopa/fa30339d523adb3e6fe776628b5625c7?reference=17,1984.0,C[C](N)(CC1=CC(O)=C(O)C=C1)C(O)=O
Methylphenidate Hydrochloride,COC(=O)C(C1CCCCN1)C1=CC=CC=C1,Hepatocellular injury,Human,-1.8573324964312685,Repeated,Oral,"FDA approval package document: Approval Package 208607/S-000 Part 01, page:11 PDF 18270k",https://www.pharmapendium.com/browse/fda/Methylphenidate Hydrochloride/277c9ab81a81fabd941f9704c52717d5?reference=11,2017.0,COC(=O)C(C1CCCCN1)C1=CC=CC=C1
Micafungin Sodium,[H][C@@]12C[C@@H](O)CN1C(=O)[C@@H](NC(=O)[C@H](C[C@@H](O)[C@@H](O)NC(=O)[C@]1([H])[C@@H](O)[C@@H](C)CN1C(=O)[C@@H](NC(=O)[C@@H](NC2=O)[C@H](O)[C@@H](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[C@H](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[C@@H](C)O,Hepatocellular injury,Human,-2.1760912590556813,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 021754/S-000 Part 05, page:28 PDF 7018k",https://www.pharmapendium.com/browse/fda/Micafungin Sodium/62a7393abbe4b160a8e92ee0ad5d03f5?reference=28,2005.0,[H][C]12C[CH](O)CN1C(=O)[CH](NC(=O)[CH](C[CH](O)[CH](O)NC(=O)[C]1([H])[CH](O)[CH](C)CN1C(=O)[CH](NC(=O)[CH](NC2=O)[CH](O)[CH](O)C1=CC=C(O)C(OS([O-])(=O)=O)=C1)[CH](O)CC(N)=O)NC(=O)C1=CC=C(C=C1)C1=NOC(=C1)C1=CC=C(OCCCCC)C=C1)[CH](C)O
Milnacipran Hydrochloride,CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C1=CC=CC=C1,Hepatocellular injury,Human,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022256/S-000 Part 02, page:9 PDF 6827k",https://www.pharmapendium.com/browse/fda/Milnacipran Hydrochloride/4c84f50c0997fbb4cfe3c70b7e24504a?reference=9,2008.0,CCN(CC)C(=O)[C]1(C[CH]1CN)C1=CC=CC=C1
Mitotane,ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=C(Cl)C=CC=C1,Hepatocellular injury,Human,-3.7781512503836434,Repeated,Oral,"EMA approval document: ANNEX I, page:4 PDF 425k",https://www.pharmapendium.com/browse/ema/Mitotane/a7a1adb13e3e762744b74fe4e101a823?reference=4,2020.0,ClC(Cl)C(C1=CC=C(Cl)C=C1)C1=C(Cl)C=CC=C1
Montelukast Sodium,CC(C)(O)C1=CC=CC=C1CC[C@@H](SCC1(CC1)CC([O-])=O)C1=CC=CC(\C=C\C2=CC=C3C=CC(Cl)=CC3=N2)=C1,Hepatocellular injury,Human,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 020829/S-033 Part 01, page:22 PDF 1055k",https://www.pharmapendium.com/browse/fda/Montelukast Sodium/449e305b67f12616effeef3afdb220cc?reference=22,2005.0,CC(C)(O)C1=CC=CC=C1CC[CH](SCC1(CC1)CC([O-])=O)C1=CC=CC(\C=C\C2=CC=C3C=CC(Cl)=CC3=N2)=C1
Mycophenolate Mofetil,COC1=C(C)C2=C(C(=O)OC2)C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1,Hepatocellular injury,Human,-3.5440680443502757,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 050722, page:74 PDF 2507k",https://www.pharmapendium.com/browse/fda/Mycophenolate Mofetil/51abf60038d80281d34789f640bfc199?reference=74,1995.0,COC1=C(C)C2=C(C(=O)OC2)C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1
Naltrexone,[H][C@@]12CC3=C4C(O[C@H]5C(=O)CC[C@]1(O)[C@@]45CCN2CC1CC1)=C(O)C=C3,Hepatocellular injury,Human,0,Repeated,Intramuscular,"FDA approval package document: Label 021897/S-005, S-010, page:7 PDF 428k",https://www.pharmapendium.com/browse/fda/Naltrexone/637c04c725c9b1a7aa8b473438e77230?reference=7,2010.0,[H][C]12CC3=C4C(O[CH]5C(=O)CC[C]1(O)[C]45CCN2CC1CC1)=C(O)C=C3
Nizatidine,CN\C(NCCSCC1=CSC(CN(C)C)=N1)=C\N(=O)=O,Hepatocellular injury,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Printed Labeling 021494/S-000, page:8 PDF 972k",https://www.pharmapendium.com/browse/fda/Nizatidine/48bb51b3c36a8fa9cb390213dfb5f04b?reference=8,2004.0,CN\C(NCCSCC1=CSC(CN(C)C)=N1)=C\N(=O)=O
Nomifensine,CN1CC(C2=CC=CC=C2)C2=C(C1)C(N)=CC=C2,Hepatocellular injury,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 018224 Part 07, page:10 PDF 1209k",https://www.pharmapendium.com/browse/fda/Nomifensine/d6b5fd068e8382f8922f92c1191b2991?reference=10,1984.0,CN1CC(C2=CC=CC=C2)C2=C(C1)C(N)=CC=C2
Omeprazole Magnesium,COC1=CC=C2[N-]C(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C,Hepatocellular injury,Human,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Label 022056/S-000, page:11 PDF 2266k",https://www.pharmapendium.com/browse/fda/Omeprazole Magnesium/c3fb9402da19707d4ab213bad3649554?reference=11,,COC1=CC=C2[N-]C(=NC2=C1)S(=O)CC1=NC=C(C)C(OC)=C1C
Orlistat,CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O,Hepatocellular injury,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021887/S-000 Part 01, page:44 PDF 4480k",https://www.pharmapendium.com/browse/fda/Orlistat/3f97e8190e694a8cb2e2e90a1f1afa61?reference=44,2005.0,CCCCCCCCCCC[CH](C[CH]1OC(=O)[CH]1CCCCCC)OC(=O)[CH](CC(C)C)NC=O
Oxcarbazepine,NC(=O)N1C2=CC=CC=C2CC(=O)C2=CC=CC=C12,Hepatocellular injury,Human,-3.5563025007672873,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021014/S-000 Part 06, page:27 PDF 1647k",https://www.pharmapendium.com/browse/fda/Oxcarbazepine/44b120c1ccabb76ebd73a0eb1292f6c2?reference=27,1999.0,NC(=O)N1C2=CC=CC=C2CC(=O)C2=CC=CC=C12
Pantoprazole Sodium,COC1=C(OC)C(=NC=C1)\C=S([O-])\C1=NC2=CC(OC(F)F)=CC=C2N1,Hepatocellular injury,Human,-2.380211241711606,Repeated,Intravenous,"FDA approval package document: Label 209463/S-000, page:10 PDF 2476k",https://www.pharmapendium.com/browse/fda/Pantoprazole Sodium/518b2c6e7f8c875eddc46c9f70b9e25d?reference=10,2017.0,COC1=C(OC)C(=NC=C1)\C=S([O-])\C1=NC2=CC(OC(F)F)=CC=C2N1
Pazopanib Hydrochloride,CN1N=C2C=C(C=CC2=C1C)N(C)C1=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=NC=C1,Hepatocellular injury,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 022465/S-000, page:77 PDF 1560k",https://www.pharmapendium.com/browse/fda/Pazopanib Hydrochloride/893f6f8879191ff31ae434f60b8e4e98?reference=77,2009.0,CN1N=C2C=C(C=CC2=C1C)N(C)C1=NC(NC2=CC=C(C)C(=C2)S(N)(=O)=O)=NC=C1
Phenytoin,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1,Hepatocellular injury,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Approval Package 008762/S-039 Part 01, page:16 PDF 427k",https://www.pharmapendium.com/browse/fda/Phenytoin/f663eb919dfb8c88d5bfb73c9391cea1?reference=16,2011.0,O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1
Phenytoin Sodium,[O-]C1=NC(C(=O)N1)(C1=CC=CC=C1)C1=CC=CC=C1,Hepatocellular injury,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 040621/S-000 Part 01, page:8 PDF 9629k",https://www.pharmapendium.com/browse/fda/Phenytoin Sodium/54e51c00bc27022bd303d2a10f9b6bd3?reference=8,2006.0,[O-]C1=NC(C(=O)N1)(C1=CC=CC=C1)C1=CC=CC=C1
Pioglitazone Hydrochloride,CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1,Hepatocellular injury,Human,-1.6532125137753437,Repeated,Oral,"EMA approval document: ANNEX I, page:5 PDF 210k",https://www.pharmapendium.com/browse/ema/Pioglitazone Hydrochloride/d1bc2de330371edc380e88a81157914a?reference=5,2021.0,CCC1=CN=C(CCOC2=CC=C(CC3SC(=O)NC3=O)C=C2)C=C1
Posaconazole,CC[C@@H]([C@H](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@@](C2)(CN2C=NC=N2)C2=C(F)C=C(F)C=C2)C=C1,Hepatocellular injury,Human,-2.9030899869919438,Repeated,Oral,"EMA approval document: ANNEX I, page:11 PDF 277k",https://www.pharmapendium.com/browse/ema/Posaconazole/e50e7cb22d5e0b8ad6c3a5f7f0fda6d4?reference=11,2019.0,CC[CH]([CH](C)O)N1N=CN(C1=O)C1=CC=C(C=C1)N1CCN(CC1)C1=CC=C(OC[CH]2CO[C](C2)(CN2C=NC=N2)C2=C(F)C=C(F)C=C2)C=C1
Pregabalin,CC(C)C[C@H](CN)CC(O)=O,Hepatocellular injury,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021724/S-000 Part 02, page:76 PDF 6799k",https://www.pharmapendium.com/browse/fda/Pregabalin/4c007e1e38c4a693d58614dbb362044b?reference=76,2005.0,CC(C)C[CH](CN)CC(O)=O
Quizartinib Dihydrochloride,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=CC(OCCN5CCOCC5)=CC=C34)=N2)=NO1,Hepatocellular injury,Human,-1.7781512503836436,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/CHMP/602286/2019; EMEA/H/C/004468/0000, page:89 PDF 5534k",https://www.pharmapendium.com/browse/ema/Quizartinib Dihydrochloride/e5a1774afc92002d3e3710192a619e0e?reference=89,2019.0,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C2=CN3C(SC4=CC(OCCN5CCOCC5)=CC=C34)=N2)=NO1
Rabeprazole Sodium,COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3[N-]2)=NC=C1,Hepatocellular injury,Human,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Approval Package 020973/S-009 Part 02, page:86 PDF 14721k",https://www.pharmapendium.com/browse/fda/Rabeprazole Sodium/6b3f55d6bf0ad42f82ef4ae04d59ca5e?reference=86,2002.0,COCCCOC1=C(C)C(CS(=O)C2=NC3=CC=CC=C3[N-]2)=NC=C1
Ranitidine Hydrochloride,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C\N(=O)=O,Hepatocellular injury,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021698/S-000, page:109 PDF 7752k",https://www.pharmapendium.com/browse/fda/Ranitidine Hydrochloride/d649577b6b69cdfb36e83266f39471d9?reference=109,2004.0,CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C\N(=O)=O
Regorafenib,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1,Hepatocellular injury,Human,-2.2041199826559246,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 203085/S-000 Part 03, page:13 PDF 387k",https://www.pharmapendium.com/browse/fda/Regorafenib/3cdcf260159befd3ad96758842487521?reference=13,2012.0,CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1
Rifampin,CO[C@H]1\C=C\O[C@@]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)C(\C=N\N1CCN(C)CC1)=C2O,Hepatocellular injury,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Approval Package 050429, page:5 PDF 4018k",https://www.pharmapendium.com/browse/fda/Rifampin/4c395f8c75dbc0cabc0e90e4b0ff0d05?reference=5,1971.0,CO[CH]1\C=C\O[C]2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)\C(C)=C/C=C/[CH](C)[CH](O)[CH](C)[CH](O)[CH](C)[CH](OC(C)=O)[CH]1C)C(\C=N\N1CCN(C)CC1)=C2O
Risperidone,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1,Hepatocellular injury,Human,-1.2041199826559248,Repeated,Oral,"FDA approval package document: Approval Package 020588/S-004, page:20 PDF 5904k",https://www.pharmapendium.com/browse/fda/Risperidone/325911b581eedcab687690f8ef005a7b?reference=20,2002.0,CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCCC2=N1
Ritonavir,CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1,Hepatocellular injury,Human,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Label 020945/S-026; 020659/S-047, page:31 PDF 2773k",https://www.pharmapendium.com/browse/fda/Ritonavir/4b27276f9cf53709b84d1feb2499dfa0?reference=31,2009.0,CC(C)[CH](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[CH](C[CH](O)[CH](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
Rivaroxaban,ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O,Hepatocellular injury,Human,-1.3010299956639813,Repeated,Oral,"EMA approval document: ANNEX I, page:12 PDF 1522k",https://www.pharmapendium.com/browse/ema/Rivaroxaban/f7df462dd06876f288288ba9d48e87d0?reference=12,2020.0,ClC1=CC=C(S1)C(=O)NC[CH]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O
Sotagliflozin,CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[C@@H]2O[C@H](SC)[C@@H](O)[C@H](O)[C@H]2O)C=C1,Hepatocellular injury,Human,-2.6020599913279625,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/178275/2019; EMEA/H/C/004889/0000, page:97 PDF 3959k",https://www.pharmapendium.com/browse/ema/Sotagliflozin/2fd7b3e9fdb0cb01d5737a3b365d1052?reference=97,2019.0,CCOC1=CC=C(CC2=C(Cl)C=CC(=C2)[CH]2O[CH](SC)[CH](O)[CH](O)[CH]2O)C=C1
Stiripentol,CC(C)(C)C(O)\C=C\C1=CC=C2OCOC2=C1,Hepatocellular injury,Human,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 206709/S-000; 207223/S-000 Part 01, page:173 PDF 2233k",https://www.pharmapendium.com/browse/fda/Stiripentol/2fa86c5ab0867c548d9f0e4245ea5508?reference=173,2018.0,CC(C)(C)C(O)\C=C\C1=CC=C2OCOC2=C1
Sulfasalazine,OC(=O)C1=C(O)C=CC(=C1)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1,Hepatocellular injury,Human,-3.6020599913279625,Repeated,Oral,"FDA approval package document: Label 021243/S-000, page:9 PDF 874k",https://www.pharmapendium.com/browse/fda/Sulfasalazine/cf8a0c6ad016a2a507078cca2fee3df1?reference=9,2000.0,OC(=O)C1=C(O)C=CC(=C1)\N=N\C1=CC=C(C=C1)S(=O)(=O)NC1=CC=CC=N1
Tacrine Hydrochloride,NC1=C2C=CC=CC2=NC2=C1CCCC2,Hepatocellular injury,Human,-1.6020599913279623,Repeated,Oral,"FDA approval package document: Approval Package 020070/S-001, S-003, S-004, S-006 Part 05, page:60 PDF 6252k",https://www.pharmapendium.com/browse/fda/Tacrine Hydrochloride/b3fc55c16692ec128bec43054e8bff77?reference=60,1993.0,NC1=C2C=CC=CC2=NC2=C1CCCC2
Tacrolimus,[H][C@]12O[C@](O)([C@H](C)C[C@@H]1OC)C(=O)C(=O)N1CCCC[C@H]1C(=O)O[C@@H]([C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)\C=C(C)\C[C@H](C)C[C@@H]2OC)C(\C)=C\[C@H]1CC[C@@H](O)[C@H](C1)OC,Hepatocellular injury,Human,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Medical Officer Review 050708, page:89 PDF 3016k",https://www.pharmapendium.com/browse/fda/Tacrolimus/75646250a5469f39fb3d1f2a54123990?reference=89,1994.0,[H][C]12O[C](O)([CH](C)C[CH]1OC)C(=O)C(=O)N1CCCC[CH]1C(=O)O[CH]([CH](C)[CH](O)CC(=O)[CH](CC=C)\C=C(C)\C[CH](C)C[CH]2OC)C(\C)=C\[CH]1CC[CH](O)[CH](C1)OC
Telithromycin,[H][C@]12[C@@H](C)C(=O)[C@H](C)C[C@@](C)(OC)[C@H](O[C@@H]3O[C@H](C)C[C@@H]([C@H]3O)N(C)C)[C@@H](C)C(=O)[C@@H](C)C(=O)O[C@H](CC)[C@@]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CN=CC=C1,Hepatocellular injury,Human,-2.9030899869919438,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 021144/S-000 Part 08, page:10 PDF 1778k",https://www.pharmapendium.com/browse/fda/Telithromycin/4d0f807a97277b070a190374a8d0f7d1?reference=10,2000.0,[H][C]12[CH](C)C(=O)[CH](C)C[C](C)(OC)[CH](O[CH]3O[CH](C)C[CH]([CH]3O)N(C)C)[CH](C)C(=O)[CH](C)C(=O)O[CH](CC)[C]1(C)OC(=O)N2CCCCN1C=NC(=C1)C1=CN=CC=C1
Tizanidine Hydrochloride,ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1,Hepatocellular injury,Human,-1.5563025007672873,Repeated,Oral,"FDA approval package document: Medical Officer Review 020397, page:8 PDF 728k",https://www.pharmapendium.com/browse/fda/Tizanidine Hydrochloride/fadd8cf1a4115fd6ce090d88629487af?reference=8,1994.0,ClC1=C(NC2=NCCN2)C2=NSN=C2C=C1
Tolcapone,CC1=CC=C(C=C1)C(=O)C1=CC(O)=C(O)C(=C1)N(=O)=O,Hepatocellular injury,Human,-0.47712125471966244,Repeated,Oral,"EMA approval document: ANNEX I, page:9 PDF 231k",https://www.pharmapendium.com/browse/ema/Tolcapone/19ace9f6328435d7347f1b519cde4e78?reference=9,2020.0,CC1=CC=C(C=C1)C(=O)C1=CC(O)=C(O)C(=C1)N(=O)=O
Tolvaptan,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2,Hepatocellular injury,Human,-2.0791812460476247,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 204441/S-000 Part 08, page:18 PDF 6791k",https://www.pharmapendium.com/browse/fda/Tolvaptan/871b836198c6b848f18a9f5f006a5eb4?reference=18,2013.0,CC1=C(C=CC=C1)C(=O)NC1=CC(C)=C(C=C1)C(=O)N1CCCC(O)C2=C1C=CC(Cl)=C2
Topiramate,[H][C@@]12OC(C)(C)O[C@]1(COS(N)(=O)=O)OC[C@H]1OC(C)(C)O[C@@H]21,Hepatocellular injury,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Medical/Clinical Review 020505/S-037; 020844/S-031, page:40 PDF 3354k",https://www.pharmapendium.com/browse/fda/Topiramate/f2ff42890eb6e91aab71b53922da427b?reference=40,2009.0,[H][C]12OC(C)(C)O[C]1(COS(N)(=O)=O)OC[CH]1OC(C)(C)O[CH]21
Tramadol Hydrochloride,COC1=CC(=CC=C1)[C@]1(O)CCCC[C@H]1CN(C)C,Hepatocellular injury,Human,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 020281 Part 04, page:30 PDF 4425k",https://www.pharmapendium.com/browse/fda/Tramadol Hydrochloride/4b70086f27976254a969bfaf0b09086e?reference=30,1995.0,COC1=CC(=CC=C1)[C]1(O)CCCC[CH]1CN(C)C
Tucatinib,CC1=CC(NC2=C3C=C(NC4=NC(C)(C)CO4)C=CC3=NC=N2)=CC=C1OC1=CC2=NC=NN2C=C1,Hepatocellular injury,Human,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Label 213411/S-001, page:6 PDF 999k",https://www.pharmapendium.com/browse/fda/Tucatinib/f1a86e7fa41a3766a3afda32e98fe0de?reference=6,2020.0,CC1=CC(NC2=C3C=C(NC4=NC(C)(C)CO4)C=CC3=NC=N2)=CC=C1OC1=CC2=NC=NN2C=C1
Ulipristal Acetate,[H][C@@]12CCC3=CC(=O)CCC3=C1[C@H](C[C@@]1(C)[C@@]2([H])CC[C@]1(OC(C)=O)C(C)=O)C1=CC=C(C=C1)N(C)C,Hepatocellular injury,Human,-1.0,Repeated,Oral,"EMA approval document: Assessment Report EMA/442745/2018; EMEA/H/A-20/1460/C/2041/0043, page:8 PDF 310k",https://www.pharmapendium.com/browse/ema/Ulipristal Acetate/983280aa4e864a17a4652c9ce1ceb851?reference=8,2018.0,[H][C]12CCC3=CC(=O)CCC3=C1[CH](C[C]1(C)[C]2([H])CC[C]1(OC(C)=O)C(C)=O)C1=CC=C(C=C1)N(C)C
Venlafaxine Hydrochloride,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1,Hepatocellular injury,Human,-2.574031267727719,Repeated,Oral,"FDA approval package document: Approval Package 076565/S-000 Part 01, page:12 PDF 430k",https://www.pharmapendium.com/browse/fda/Venlafaxine Hydrochloride/5cd234a6c0473f68efdb6f0cc83b8642?reference=12,2010.0,COC1=CC=C(C=C1)C(CN(C)C)C1(O)CCCCC1
Voriconazole,C[C@@H](C1=C(F)C=NC=N1)[C@](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F,Hepatocellular injury,Human,-1.0791812460476249,Repeated,Intravenous,"FDA approval package document: Approval Package 021266/S-009, 021267/S-009, 021630/S-003 Part 03, page:10 PDF 309k",https://www.pharmapendium.com/browse/fda/Voriconazole/6bf2dd491c6903c4f6aa215436a65f75?reference=10,2004.0,C[CH](C1=C(F)C=NC=N1)[C](O)(CN1C=NC=N1)C1=CC=C(F)C=C1F
Zalcitabine,NC1=NC(=O)N(C=C1)[C@H]1CC[C@@H](CO)O1,Hepatocellular injury,Human,-1.3979400086720377,Repeated,Oral,"FDA approval package document: Approval Package 020199 Part 01, page:20 PDF 3966k",https://www.pharmapendium.com/browse/fda/Zalcitabine/7516791f2c2ebfd4e1d211931a39b97b?reference=20,1992.0,NC1=NC(=O)N(C=C1)[CH]1CC[CH](CO)O1
Zanamivir,[H][C@]1(OC(=C[C@H](NC(N)=N)[C@H]1NC(C)=O)C(O)=O)[C@H](O)[C@H](O)CO,Hepatocellular injury,Human,-2.7781512503836434,Repeated,Intravenous,"EMA approval document: Public Assessment Report EMA/CHMP/851480/2018; EMEA/H/C/004102/0000, page:124 PDF 2375k",https://www.pharmapendium.com/browse/ema/Zanamivir/0160f7132f67bf85b6bfb2d976c2fd6f?reference=124,2019.0,[H][C]1(OC(=C[CH](NC(N)=N)[CH]1NC(C)=O)C(O)=O)[CH](O)[CH](O)CO
Zonisamide,NS(=O)(=O)CC1=NOC2=CC=CC=C12,Hepatocellular injury,Human,-2.6989700043360187,Repeated,Oral,"EMA approval document: ANNEX I, page:13 PDF 567k",https://www.pharmapendium.com/browse/ema/Zonisamide/9fa29fe42c687f7668ad4aba68f026e0?reference=13,2021.0,NS(=O)(=O)CC1=NOC2=CC=CC=C12
